Survival Analysis of Adjuvant Chemotherapy With S-1 Plus Cisplatin for Stage III Gastric Cancer

Gastric Cancer - Germany
doi 10.1007/s10120-013-0264-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Survival Benefit of Neoadjuvant Chemotherapy With S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis

Annals of Surgical Oncology
OncologySurgery
2019English

Feasibility Study of Adjuvant Chemotherapy With S-1 (TS-1; Tegafur, Gimeracil, Oteracil Potassium) for Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2004English

Relapse-Associated microRNA in Gastric Cancer Patients After S-1 Adjuvant Chemotherapy

Oncology Reports
MedicineCancer ResearchOncology
2013English

Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur–Uracil Plus Leucovorin Versus Capecitabine

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

Factors Associated With Delayed Time to Adjuvant Chemotherapy in Stage Iii Colon Cancer

Current Oncology
Oncology
2014English

Delay in Initiation of Postoperative Adjuvant Chemotherapy With S-1 Monotherapy and Prognosis for Gastric Cancer Patients: Analysis of a Multi-Institutional Dataset

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2019English

Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation

Oncologist
Cancer ResearchMedicineOncology
2013English

P53 Expression Status Is Associated With Cancer-Specific Survival in Stage III and High-Risk Stage II Colorectal Cancer Patients Treated With Oxaliplatin-Based Adjuvant Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2019English

Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients With Extensive-Disease Small Cell Lung Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy